What are the latest figures on the chronic cough market’s size and projected CAGR?
The chronic cough market size has grown strongly in recent years. It will grow from $8.22 billion in 2024 to $8.9 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to prevalence of underlying respiratory conditions, environmental factors and air pollution, smoking and tobacco use, respiratory infections, allergies and environmental sensitivities
The chronic cough market size is expected to see strong growth in the next few years. It will grow to $12.89 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to emerging therapies targeting specific pathways, increasing understanding of reflux-related cough, global efforts in smoking cessation, environmental and occupational health policies. Major trends in the forecast period include advancements in diagnostic technologies, patient-centric approaches, therapeutic innovations in neurogenic cough, telehealth for chronic cough management, research on central sensitization.
Get Your Free Sample of The Global Chronic Cough Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12109&type=smp
Which Market drivers have played a significant role in driving the chronic cough market?
The rise in the prevalence of cough is expected to propel the growth of the chronic cough market going forward. Cough refers to a reflex action that, frequently in response to irritation, mucus, or foreign objects, helps clear the airways by ejecting air forcefully from the lungs. A persistent cough that lasts for at least eight weeks is considered chronic. Therefore, when the incidence of cough rises, so do the cases of chronic cough. For instance, in March 2022, according to the Florida Health, a US-based Department of Healthcare, in the US total of 80 patients were found in 2021, for incidences of 41.0 and 1.4 per 100,000 years, respectively. There were 28 pertussis cases recorded in 2023 among 13 countries. Furthermore, in March 2022, according to the Statens Serum Institut, a Denmark-based department of disease surveillance, the number of pertussis cases recorded increased by 41% from November 2022 to April 2023, compared to November 2021–April 2022 in Denmark. Therefore, the rise in the prevalence of cough is driving the growth of the chronic cough market.
What are the key segments within the chronic cough market?
The chronic cough market covered in this report is segmented –
1) By Drug Class: Antihistamines, Corticosteroids, Decongestants, Combination Drug, Antibiotics, Acid Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Inhalational, Injectable, Other Route Of Administrations
3) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
Subsegments:
1) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines
2) By Corticosteroids: Inhaled Corticosteroids, Systemic Corticosteroids
3) By Decongestants: Oral Decongestants, Nasal Decongestants
4) By Combination Drug: Antihistamine And Decongestant Combinations, Cough Suppressant And Expectorant Combinations
5) By Antibiotics: Macrolides, Penicillins, Cephalosporins
6) By Acid Blockers: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists
7) By Other Drug Classes: Mucolytics, Cough Suppressants, Herbal Remedies
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report
Which key players are shaping the chronic cough market?
Major companies operating in the chronic cough market include Tris Pharma Inc., Pfizer Inc., Johnson & Johnson Co, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Glaxo SmithKline Plc, Merck KGaA, Reckitt Benckiser Group plc, Glenmark Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., Mylan NV, Aurobindo Pharma Ltd., Cipla Limited, Apotex Inc., Hikma Pharmaceuticals Plc, Amneal Pharmaceuticals LLC, Mount Sinai Health System, Biocon Ltd., BELLUS Health Inc., Trevi Therapeutics Inc., Sun Pharmaceutical Industries Ltd., NeRRe Therapeutics Ltd.
Which transformative trends will shape the chronic cough market landscape?
Major companies operating in the chronic cough market are concentrating on creating innovative products such as biosimilar to strengthen their position in the market. Biosimilars are used to treat conditions like cancer, autoimmune diseases, and diabetes, offering cost-effective alternatives to existing biologics. For instance, in July 2024, according to the Sandoz, a Switzerland-based Pharmaceutical company, launched its biosimilar Pyzchiva (ustekinumab) across Europe, targeting chronic inflammatory diseases such as plaque psoriasis, psoriatic arthritis, and Crohn’s disease. This biosimilar is particularly significant as it is the first of its kind available in Europe with all reference medicine strengths, including the initiation dose for Crohn’s disease. Developed in partnership with Samsung Bioepis, Sandoz aims to enhance access to effective treatments for millions affected by these conditions. The launch reflects Sandoz’s commitment to providing affordable healthcare solutions and improving the quality of life for patients across Europe.
How do regional factors impact the chronic cough market, and which region is the largest contributor?
North America was the largest region in the chronic cough market in 2024. The regions covered in the chronic cough market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Chronic Cough Market Report 2025 Offer?
The chronic cough market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Chronic cough refers to a cough that is persistent and lasts for a long time, usually eight weeks or more. It frequently manifests as signs of an underlying illness, such as asthma, allergies, or respiratory infections.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12109
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
